Physician profile
Tomas Ganz
NPI 1083639264
$108,376.40
in general payments reported to CMS, 2019-2025
17 companies · $32K in 2025
The $32K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $19K · 2021: $12K · 2022: $16K · 2023: $10K · 2024: $7,403 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Travel and Lodging: $21K · Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,681.00 |
| Travel and Lodging | $21,359.15 |
| Food and Beverage | $267.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor (International) LTD. | $37,343.45 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $26,541.40 | 2020-2024 | Monoferric |
| American Regent | $12,001.67 | 2019-2020 | |
| Akebia Therapeutics INC | $8,131.62 | 2019-2021 | |
| Glaxosmithkline, LLC. | $6,900.00 | 2019-2023 | |
| Rockwell Medical, INC. | $4,300.00 | 2020 | |
| Incyte Corporation | $3,575.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $3,222.00 | 2021 | |
| Chugai Pharmaceutical Co., LTD. | $1,898.42 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $1,446.00 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,207.50 | 2020 | |
| Csl Behring | $723.00 | 2025 | |
| Alnylam Pharmaceuticals INC. | $615.00 | 2021 | |
| Agios Pharmaceuticals, INC. | $300.00 | 2023 | |
| Apo-Pharma INC. | $125.00 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $46.34 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Ganz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.